Finance
Novartis to acquire Avidity Biosciences for about $12 billion
Published by Global Banking & Finance Review®
Posted on October 26, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on October 26, 2025
1 min readLast updated: January 21, 2026
Novartis plans to acquire Avidity Biosciences for $12 billion, offering $72 per share. The deal includes creating a new company, Spinco, for Avidity's cardiology programs.
(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash.
Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday.
Under the terms of agreement, Avidity will separate its early-stage precision cardiology programs into a new company called Spinco.
Novartis has been actively striking deals in 2025 as it looks to bolster its drug pipeline and drive future growth, and the Financial Times reported in August that the Swiss drugmaker had approached Avidity Biosciences for a potential takeover offer.
(Reporting by Angela Christy in Bengaluru)
An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.
A pharmaceutical company is a business that develops, produces, and markets drugs or medications for use as medications to be administered to patients.
Corporate strategy is the overall plan for a diversified company, outlining how it will create value across its various business units and achieve its long-term goals.
Investment refers to the allocation of resources, usually money, in order to generate income or profit. This can include purchasing stocks, bonds, or real estate.
Explore more articles in the Finance category
